Hamidi F, Gilani N, Arabi Belaghi R, Yaghoobi H, Babaei E, Sarbakhsh P
Front Digit Health. 2023; 5:1187578.
PMID: 37621964
PMC: 10445490.
DOI: 10.3389/fdgth.2023.1187578.
Irfan M, Javed Z, Khan K, Khan N, Docea A, Calina D
Cancer Cell Int. 2022; 22(1):280.
PMID: 36076273
PMC: 9461221.
DOI: 10.1186/s12935-022-02695-8.
Ahmed K, Sun J, Chen W, Martinez I, Cheng S, Zhang W
Brief Bioinform. 2021; 22(6).
PMID: 34279571
PMC: 8575005.
DOI: 10.1093/bib/bbab264.
Ozyerli-Goknar E, Bagci-Onder T
Cancers (Basel). 2021; 13(13).
PMID: 34199020
PMC: 8267644.
DOI: 10.3390/cancers13133210.
Gu L, Li Q, Liu H, Lu X, Zhu M
Onco Targets Ther. 2020; 13:2007-2019.
PMID: 32189969
PMC: 7065918.
DOI: 10.2147/OTT.S240434.
MicroRNA-149 suppresses the proliferation and increases the sensitivity of ovarian cancer cells to cisplatin by targeting X-linked inhibitor of apoptosis.
Sun L, Zhai R, Zhang L, Zhao S
Oncol Lett. 2018; 15(5):7328-7334.
PMID: 29731888
PMC: 5920966.
DOI: 10.3892/ol.2018.8240.
MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1.
Tian S, Zhang M, Chen X, Liu Y, Lou G
Oncotarget. 2016; 7(52):87091-87099.
PMID: 27893429
PMC: 5349973.
DOI: 10.18632/oncotarget.13526.
Systems analysis identifies miR-29b regulation of invasiveness in melanoma.
Andrews M, Cursons J, Hurley D, Anaka M, Cebon J, Behren A
Mol Cancer. 2016; 15(1):72.
PMID: 27852308
PMC: 5112703.
DOI: 10.1186/s12943-016-0554-y.
The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma.
Samuel P, Carter D
Mol Diagn Ther. 2016; 21(1):59-73.
PMID: 27718164
DOI: 10.1007/s40291-016-0242-z.
Involvement of DNMT 3B promotes epithelial-mesenchymal transition and gene expression profile of invasive head and neck squamous cell carcinomas cell lines.
Chen L, Hsu W, Tseng Y, Liu D, Weng C
BMC Cancer. 2016; 16:431.
PMID: 27391030
PMC: 4938990.
DOI: 10.1186/s12885-016-2468-x.
Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.
Szajnik M, Czystowska-Kuzmicz M, Elishaev E, Whiteside T
Expert Rev Mol Diagn. 2016; 16(8):811-26.
PMID: 27268121
PMC: 5010004.
DOI: 10.1080/14737159.2016.1194758.
miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma.
Shi C, Zhang Z
Tumour Biol. 2015; 37(4):5437-43.
PMID: 26563371
DOI: 10.1007/s13277-015-4377-z.
MicroRNA-29B (mir-29b) regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3.
Teng Y, Zhang Y, Qu K, Yang X, Fu J, Chen W
Oncotarget. 2015; 6(38):40799-814.
PMID: 26512921
PMC: 4747369.
DOI: 10.18632/oncotarget.5695.
Genome-wide analysis of microRNA and mRNA expression signatures in cancer.
Li M, Fu S, Xiao H
Acta Pharmacol Sin. 2015; 36(10):1200-11.
PMID: 26299954
PMC: 4648178.
DOI: 10.1038/aps.2015.67.
Clinically relevant microRNAs in ovarian cancer.
Zhang S, Lu Z, Unruh A, Ivan C, Baggerly K, Calin G
Mol Cancer Res. 2014; 13(3):393-401.
PMID: 25304686
PMC: 4369176.
DOI: 10.1158/1541-7786.MCR-14-0424.
The role of microRNAs in ovarian cancer.
Kinose Y, Sawada K, Nakamura K, Kimura T
Biomed Res Int. 2014; 2014:249393.
PMID: 25295252
PMC: 4177088.
DOI: 10.1155/2014/249393.
miR-29b suppresses tumor growth and metastasis in colorectal cancer via downregulating Tiam1 expression and inhibiting epithelial-mesenchymal transition.
Wang B, Li W, Liu H, Yang L, Liao Q, Cui S
Cell Death Dis. 2014; 5:e1335.
PMID: 25032858
PMC: 4123095.
DOI: 10.1038/cddis.2014.304.
Role of microRNA-133a in epithelial ovarian cancer pathogenesis and progression.
Luo J, Zhou J, Cheng Q, Zhou C, Ding Z
Oncol Lett. 2014; 7(4):1043-1048.
PMID: 24944666
PMC: 3961467.
DOI: 10.3892/ol.2014.1841.
MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H, Park C, Deftereos G, Morihara J, Stern J, Hawes S
World J Surg Oncol. 2012; 10:174.
PMID: 22925189
PMC: 3449188.
DOI: 10.1186/1477-7819-10-174.
B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence.
Sun T, Gao Q, Qiu S, Zhou J, Wang X, Yi Y
Cancer Immunol Immunother. 2012; 61(11):2171-82.
PMID: 22729558
PMC: 11029627.
DOI: 10.1007/s00262-012-1278-5.